Dataset from A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00012190
下载链接
链接失效反馈官方服务：
资源简介：
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard of Care (SoC) in patients admitted to hospital for Acute Heart Failure (AHF).
创建时间：
2025-12-16
